Flagship Harbor Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Flagship Harbor Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-515	Closed	-$58K	–	1965
2020 Q3	$58K	Hold	515	–	–	0.01%	811
2020 Q2	$57K	Hold	515	–	–	0.01%	817
2020 Q1	$46K	Hold	515	–	–	0.01%	776
2019 Q4	$56K	Buy	515 +15	+3%	+$1.6K	0.01%	782
2019 Q3	$48K	Hold	500	–	–	0.01%	788
2019 Q2	$65K	Hold	500	–	–	0.01%	683
2019 Q1	$67K	Hold	500	–	–	0.01%	674
2018 Q4	$48K	Sell	500 -270	-35%	-$31.9K	0.01%	734
2018 Q3	$106K	Buy	770 +98	+15%	+$12.3K	0.02%	579
2018 Q2	$83K	Buy	+672	New	+$78.5K	0.02%	636

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Flagship Harbor Advisors's ALXN Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 515 shares — an estimated $58K sold.

Flagship Harbor Advisors first reported a position in ALXN in Q2 2018 and held it in 10 quarters. The position peaked at $106K in Q3 2018. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Flagship Harbor Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 515 Alexion Pharmaceuticals shares in Q4 2020, an estimated $58K.
Flagship Harbor Advisors first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Flagship Harbor Advisors's Alexion Pharmaceuticals position peaked at $106K in Q3 2018.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.